NGAL and KIM-1 – early urinary biomarkers of nephrotoxicity mediated by cisplatin: Observational study
- Authors: Grechukhina K.S.1,2, Chebotareva N.V.1,3, Zhukova L.G.2, Dorofeev A.S.2, Krasnova T.N.1
-
Affiliations:
- Lomonosov Moscow State University
- Loginov Moscow Clinical Scientific Center
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 24, No 1 (2022)
- Pages: 119-124
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/88111
- DOI: https://doi.org/10.26442/18151434.2022.1.201285
- ID: 88111
Cite item
Full Text
Abstract
Background. Cisplatin is widely used in modern oncological practice. Despite high efficacy treatment with cisplatin is conjugated with high risk of nephrotoxicity. Approximately one third of patients develop renal disfunction after first injection of cisplatin. In clinical practice serum creatinine elevation is used as a marker of renal damage, which is observed after failure of 50% of kidney function. That is why the finding of early biomarker of nephrotoxicity is still an issue. NGAL and KIM-1 are markers of renal damage, the predictive value of which has been described in cardiac surgery and resuscitation practice: an increase in the concentration of these markers in urine precedes the development of renal damage, both ischemic and direct toxic.
Aim. To evaluate the role of NGAL and KIM-1 in urine as early markers of cisplatin nephrotoxicity.
Materials and methods. The study included 50 patients treated with cisplatin in combination with fluoropyrimidines or paclitaxel. Prior to treatment and over a period of 8 weeks, the Friedman test was used to assess blood pressure, plasma creatinine, potassium, urea levels, daily proteinuria, urine NGAL and KIM-1 levels, and glomerular filtration rate (GFR). ROC analysis was used to assess the prognostic significance of NGAL and KIM-1 in the development of nephrotoxicity.
Results. There was a statistically significant increase in the level of urea (χ²=17.7; df 4, p=0.001), potassium (χ²=42; df 4, p<0.001), a decrease in GFR (χ²=32.3; df 4, p<0.001), the appearance of proteinuria (χ²=50.4; df 4, p<0.001). The concentration of NGAL and KIM-1 increased already one week after the start of cisplatin therapy, reaching a maximum by 8 weeks (χ²=200; df 4, p<0.001). The appearance of NGAL at a concentration of 10.743 ng/ml and KIM-1 at a concentration of 182.4 pg/ml in the first week after administration of cisplatin allows predicting the development of nephrotoxicity by the 8th week with high sensitivity (90.91%) and specificity (94.87%), AUC 0.96.
Conclusion. The appearance of NGAL and KIM-1 in urine already in the first week of treatment allows predicting the development of nephrotoxicity – a decrease in GFR of less than 60 ml/min by the 8th week of therapy with high sensitivity and specificity. Both biomarkers can be considered early prognostically significant.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Katerina S. Grechukhina
Lomonosov Moscow State University; Loginov Moscow Clinical Scientific Center
Author for correspondence.
Email: dr.grechukhina@gmail.com
ORCID iD: 0000-0002-0616-5477
Graduate Student
Russian Federation, Moscow; MoscowNatalia V. Chebotareva
Lomonosov Moscow State University; Sechenov First Moscow State Medical University (Sechenov University)
Email: dr.grechukhina@gmail.com
ORCID iD: 0000-0003-2128-8560
D. Sci. (Med.)
Russian Federation, Moscow; MoscowLiudmila G. Zhukova
Loginov Moscow Clinical Scientific Center
Email: dr.grechukhina@gmail.com
ORCID iD: 0000-0003-4848-6938
D. Sci. (Med.), Prof. RAS
Russian Federation, MoscowAlexey S. Dorofeev
Loginov Moscow Clinical Scientific Center
Email: dr.grechukhina@gmail.com
ORCID iD: 0000-0001-9754-7579
Res. Assist.
Russian Federation, MoscowTatiana N. Krasnova
Lomonosov Moscow State University
Email: dr.grechukhina@gmail.com
ORCID iD: 0000-0002-7647-3942
Cand. Sci. (Med.)
Russian Federation, MoscowReferences
- Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014;2014:967826. doi: 10.1155/2014/967826
- Browning RJ, Reardon PJT, Parhizkar M, et al. Drug Delivery Strategies for Platinum-Based Chemotherapy. ACS Nano. 2017;11:8560-78. doi: 10.1021/acsnano.7b04092
- Dasari S, Tchounwou P. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-78. doi: 10.1016/j.ejphar.2014.07.025
- Hill JM, Speer RJ. Organo-platinum complexes as antitumor agents. Anticancer Res. 1982;2:173-85.
- Kostovska I, Trajkovska T, Topuzovska S, et al. Urinary nephrin is earlier, more sensitive and specific marker of diabetic nephropathy than microalbuminuria Urinarni nefrin je raniji, osetljiviji i specifičniji marker dijabetesne nefropatije nego mikroalbuminurija. J Med Biochem. 2020;39(1):83-90. doi: 10.2478/jomb-2019-0026
- Atilano-Roque A, Wen X, Aleksunes LM, et al. Nrf2 activators as potential modulators of injury in human kidney cells. Toxicol Rep. 2016;3:153-9. doi: 10.1016/j.toxrep.2016.01.006
- Hauser PV, Collino F, Bussolati B, et al. Nephrin and endothelial injury. Curr Opin Nephrol Hypertens. 2009;18:3-8. doi: 10.1097/MNH.0b013e32831a4713
- McCullough PA, Bouchard J, Waikar SS, et al. ADQI Consensus on AKI Biomarkers and Cardiorenal Syndromes. Contrib Nephrol. 2013;182:13-29. doi: 10.1159/000349963
- Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365:1231-8. doi: 10.1016/S0140-6736(05)74811-X
- Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol. 2004;22:3113-9. doi: 10.1200/JCO.2004.04.170
- Yuen PST, Jo SK, Holly MK, et al. Ischemic and nephrotoxic acute renal failure are distinguished by their broad transcriptomic responses. Physiol Genomics. 2006;25:375-86. doi: 10.1152/physiolgenomics.00223.2005
- Wagener G, Gubitosa G, Wang S, et al. Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery. Am J Kidney Dis. 2008;52:425-33. doi: 10.1053/j.ajkd.2008.05.018
- Devarajan P. Review: Neutrophil gelatinase-associated lipocalin: A troponin-like biomarker for human acute kidney injury. Nephrology. 2010;15:419-28. doi: 10.1111/j.1440-1797.2010.01317.x
- Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol. 2010;28:478-85. doi: 10.1038/nbt.1623
- Bonventre J. Kidney injury molecule-1 (KIM-1): A urinary biomarker and much more. Nephrol Dial Transplant. 2009;24:3265-8. doi: 10.1093/ndt/gfp010
- Von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602-8. doi: 10.1200/JCO.2005.07.757
- Thongprasert S, Napapan S, Charoentum C, et al. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol. 2005;16:279-81. doi: 10.1093/annonc/mdi046
- Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435-42. doi: 10.1200/JCO.2007.13.9378
- Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20:807-15. doi: 10.1093/annonc/mdn713
- Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarker qualification submission: A dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol. 2010;28:455-62. doi: 10.1038/nbt.1625
- Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4:889-901. doi: 10.1517/14656566.4.6.889
- Rizo-Topete LM, Rosner MH, Ronco C. Acute kidney injury risk assessment and the nephrology rapid response team. Blood Purif. 2017;43:82-8. doi: 10.1159/000452402
- Shao X, Tian L, Xu W, et al. Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: A meta-analysis. PLoS ONE. 2014;9. doi: 10.1371/journal.pone.0084131
- Mishra J, Mori K, Ma Q, et al. Neutrophil gelatinase-associated lipocalin: A novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol. 2004;24:307-15. doi: 10.1159/000078452
- Wagener G, Gubitosa G, Wang S, et al. Increased incidence of acute kidney injury with aprotinin use during cardiac surgery detected with urinary NGAL. Am J Nephrol. 2008;28:576-82. doi: 10.1159/000115973
- Cruz DN, de Cal M, Garzotto F, et al. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med. 2010;36:444-51. doi: 10.1007/s00134-009-1711-1
- Nguyen MT, Devarajan P. Biomarkers for the early detection of acute kidney injury. Pediatr Nephrol. 2008;23:2151-7. doi: 10.1007/s00467-007-0470-x
- Wheeler DS, Devarajan P, Ma Q, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit Care Med. 2008;36:1297-303. doi: 10.1097/CCM.0b013e318169245a
- Nickolas TL, O’Rourke MJ, Yang J, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med. 2008;148:810-9. doi: 10.7326/0003-4819-148-11-200806030-00003